You have 9 free searches left this month | for more free features.

nilotinib

Showing 1 - 25 of 252

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

Recruiting
  • Metastatic Melanoma
  • BRAF Gene Mutation
  • Nilotinib 100mg
  • +5 more
  • Lexington, Kentucky
    Markey Cancer Center
Jul 22, 2022

Tumors Trial run by the NCI (Nilotinib and Paclitaxel)

Recruiting
  • Neoplasms
  • Nilotinib and Paclitaxel
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 19, 2023

Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial (Biopsy, Biospecimen Collection, Computed Tomography)

Not yet recruiting
  • Metastatic Malignant Solid Neoplasm
  • Refractory Malignant Solid Neoplasm
  • Biopsy
  • +5 more
  • (no location specified)
Nov 8, 2022

Solid Tumors Trial run by the National Cancer Institute (NCI) (Nilotinib + Paclitaxel)

Recruiting
  • Solid Tumors
  • Nilotinib + Paclitaxel
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 24, 2022

Acute Lymphoblastic Leukemia (ALL) Trial (Nilotinib)

No longer available
  • Acute Lymphoblastic Leukemia (ALL)
  • Nilotinib
  • (no location specified)
Aug 5, 2022

Peritoneal Carcinomatosis, Peritoneal Tumors, Ovarian Cancer Trial run by the National Cancer Institute (NCI) (Paclitaxel,

Not yet recruiting
  • Peritoneal Carcinomatosis
  • +7 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Trial (Asciminib, Nilotinib)

Not yet recruiting
  • Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
  • (no location specified)
Jul 11, 2022

Chronic Myeloid Leukemia Trial in New York (Nilotinib)

Completed
  • Chronic Myeloid Leukemia
  • Nilotinib
  • New York, New York
    Weill Cornell Medical College
Mar 24, 2022

Chronic Myeloid Leukemia, Chronic Phase, Nilotinib Trial in Shenzhen (Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Nilotinib
  • Nilotinib
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Mar 15, 2022

GIST and CML Trial in Worldwide (AMN107)

Active, not recruiting
  • GIST and CML
  • Nilotinib
  • Albany, New York
  • +32 more
Oct 4, 2022

Chronic Myelogenous Leukemia Trial in Beirut (Nilotinib)

Recruiting
  • Chronic Myelogenous Leukemia
  • Nilotinib
  • Beirut, Lebanon
    American University of Beirut Medical Center
Feb 14, 2022

Gastrointestinal Stromal Tumors Trial in Worldwide (Nilotinib)

Active, not recruiting
  • Gastrointestinal Stromal Tumors
  • Nilotinib
  • HUS, Finland
  • +6 more
Apr 19, 2022

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Trial in France (Nilotinib)

Completed
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Nilotinib
  • Angers, France
  • +9 more
Aug 17, 2022

Alzheimer Trial (Nilotinib BE 84mg, Nilotinib BE 112 mg, Placebo)

Not yet recruiting
  • Alzheimer Disease
  • Nilotinib BE 84mg
  • +2 more
  • (no location specified)
Nov 30, 2021

Chordoma Trial in Boston (Nilotinib, Radiation therapy)

Active, not recruiting
  • Chordoma
  • Nilotinib
  • Radiation therapy
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 27, 2021

Ataxia, Cerebellar, Ataxia, Progressive Trial in Seoul (Nilotinib)

Completed
  • Ataxia, Cerebellar
  • Ataxia, Progressive
  • Nilotinib
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Sep 23, 2021

Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and

Completed
  • Leukemia
  • No Intervention
  • Cambridge, Massachusetts
    Takeda
Feb 28, 2023

Hypereosinophilic Syndrome (HES) Trial (Nilotinib)

No longer available
  • Hypereosinophilic Syndrome (HES)
  • Nilotinib
  • (no location specified)
Sep 14, 2021

Chronic Phase Chronic Myeloid Leukemia Trial in Bruxelles (Ponatinib 30 mg QD, Ponatinib 15 mg QD, Nilotinib 400 mg BID)

Terminated
  • Chronic Phase Chronic Myeloid Leukemia
  • Ponatinib 30 mg QD
  • +2 more
  • Bruxelles, Belgium
    Cliniques Universitaire Saint-Luc (Site 058)
Oct 28, 2021

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic

Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 15, 2022

Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor Trial in United States

Active, not recruiting
  • Pigmented Villonodular Synovitis
  • +2 more
  • nilotinib
  • Santa Monica, California
  • +6 more
Jan 31, 2022

Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid Trial in Augusta, Milwaukee (Asciminib, Ascimininb +

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • +3 more
  • Augusta, Georgia
  • +1 more
Jul 14, 2022

Landscape and Real-life Treatment Outcomes in Hungary: Analysis

Completed
  • Chronic Myeloid Leukaemia
  • Budapest, Hungary
    Pfizer
Dec 15, 2022

Flumatinib Versus Nilotinib for Chronic Phase Chronic Myeloid

Recruiting
  • CML-CP; Mutation;Suboptimal Response or Failure in TKI
  • Wuhan, Hubei, China
    Weiming Li
May 31, 2021

Chronic Myeloid Leukemia Trial in Germany, Netherlands (TKI discontinuation, nilotinib)

Active, not recruiting
  • Chronic Myeloid Leukemia
  • TKI discontinuation
  • nilotinib
  • Freiburg, Baden-Württemberg, Germany
  • +14 more
Nov 4, 2021